A detailed history of Black Rock Inc. transactions in Replimune Group, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,713,791 shares of REPL stock, worth $58.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,713,791
Previous 4,612,558 2.19%
Holding current value
$58.9 Million
Previous $37.7 Million 12.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.01 - $9.46 $507,177 - $957,664
101,233 Added 2.19%
4,713,791 $42.4 Million
Q1 2024

May 10, 2024

BUY
$6.87 - $9.31 $508,867 - $689,601
74,071 Added 1.63%
4,612,558 $37.7 Million
Q4 2023

Feb 13, 2024

BUY
$6.75 - $16.18 $3.92 Million - $9.39 Million
580,541 Added 14.67%
4,538,487 $38.3 Million
Q3 2023

Nov 13, 2023

BUY
$15.96 - $22.18 $7.4 Million - $10.3 Million
463,900 Added 13.28%
3,957,946 $67.7 Million
Q2 2023

Aug 11, 2023

SELL
$15.65 - $24.1 $2 Million - $3.09 Million
-128,058 Reduced 3.54%
3,494,046 $81.1 Million
Q1 2023

May 12, 2023

BUY
$17.48 - $29.09 $10.7 Million - $17.8 Million
611,552 Added 20.31%
3,622,104 $64 Million
Q4 2022

Feb 13, 2023

BUY
$17.09 - $27.91 $4.17 Million - $6.82 Million
244,181 Added 8.83%
3,010,552 $81.9 Million
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $6.9 Million - $9.36 Million
442,331 Added 19.03%
2,766,371 $47.8 Million
Q2 2022

Aug 12, 2022

BUY
$13.32 - $19.98 $2.51 Million - $3.76 Million
188,286 Added 8.82%
2,324,040 $40.6 Million
Q1 2022

May 12, 2022

SELL
$15.24 - $29.75 $20,787 - $40,579
-1,364 Reduced 0.06%
2,135,754 $36.3 Million
Q4 2021

Feb 10, 2022

BUY
$25.43 - $34.25 $1.23 Million - $1.65 Million
48,263 Added 2.31%
2,137,118 $57.9 Million
Q3 2021

Nov 09, 2021

BUY
$28.98 - $39.54 $3.1 Million - $4.24 Million
107,132 Added 5.41%
2,088,855 $61.9 Million
Q2 2021

Aug 11, 2021

BUY
$28.5 - $39.37 $56.5 Million - $78 Million
1,981,723 New
1,981,723 $76.1 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.